Comparing of Vascular Biogenics Ltd. (VBLT) and AnaptysBio Inc. (NASDAQ:ANAB)

Vascular Biogenics Ltd. (NASDAQ:VBLT) and AnaptysBio Inc. (NASDAQ:ANAB), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation of the two firms.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vascular Biogenics Ltd. 14.31M 3.34 10.28M -0.40 0.00
AnaptysBio Inc. 8.00M 234.54 51.52M -1.83 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Vascular Biogenics Ltd. and AnaptysBio Inc.


Table 2 provides the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Vascular Biogenics Ltd. -71.84% -23.2% -19.9%
AnaptysBio Inc. -644.00% -14.9% -14%


The Current Ratio and Quick Ratio of Vascular Biogenics Ltd. are 10.4 and 10.4 respectively. Its competitor AnaptysBio Inc.’s Current Ratio is 24.1 and its Quick Ratio is 24.1. AnaptysBio Inc. can pay off short and long-term obligations better than Vascular Biogenics Ltd.

Analyst Recommendations

The next table highlights the delivered recommendations and ratings for Vascular Biogenics Ltd. and AnaptysBio Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Vascular Biogenics Ltd. 0 0 1 3.00
AnaptysBio Inc. 0 0 0 0.00

$3 is Vascular Biogenics Ltd.’s consensus price target while its potential upside is 125.56%.

Insider & Institutional Ownership

Vascular Biogenics Ltd. and AnaptysBio Inc. has shares owned by institutional investors as follows: 38% and 0%. Insiders owned 26.6% of Vascular Biogenics Ltd. shares. Competitively, AnaptysBio Inc. has 0.7% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Vascular Biogenics Ltd. -3.33% -11.45% -29.7% -57.82% -82.42% -83.66%
AnaptysBio Inc. -5.05% -17.9% -18.61% 0.71% -20.28% -29.7%

For the past year Vascular Biogenics Ltd. was more bearish than AnaptysBio Inc.


Vascular Biogenics Ltd. beats on 6 of the 11 factors AnaptysBio Inc.

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The companyÂ’s program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and has completed Phase II clinical trials for recurrent platinum-resistant ovarian cancer, as well as for iodine-resistant differentiated thyroid cancer. The companyÂ’s pipeline candidates also comprise VB-511, an anti-angiogenic candidate for oncology; and VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Or Yehuda, Israel.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The companyÂ’s proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize an anti-PD-1 antagonist antibody (TSR-042) and an anti-TIM-3 antagonist antibody (TSR-022), which are under clinical development; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 checkpoint agonist antibody (CC-90006) that is in clinical stage. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.